{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:59:27Z","timestamp":1770134367317,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10067-018-4096-0","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T13:34:05Z","timestamp":1523367245000},"page":"3201-3214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Jiang","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-2231","authenticated-orcid":false,"given":"Kun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"issue":"12","key":"4096_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30(12):2212\u20132219. https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.116","journal-title":"Vaccine"},{"issue":"2","key":"4096_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11(2):97\u2013107","journal-title":"J Viral Hepat"},{"issue":"5","key":"4096_CR3","doi-asserted-by":"publisher","first-page":"a021410","DOI":"10.1101\/cshperspect.a021410","volume":"5","author":"JH MacLachlan","year":"2015","unstructured":"MacLachlan JH, Cowie BC (2015) Hepatitis B virus epidemiology. Cold Spring Harbor Perspect Med 5(5):a021410. https:\/\/doi.org\/10.1101\/cshperspect.a021410","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"47","key":"4096_CR4","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","volume":"27","author":"X Liang","year":"2009","unstructured":"Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y (2009) Epidemiological serosurvey of hepatitis B in China\u2014declining HBV prevalence due to hepatitis B vaccination. Vaccine 27(47):6550\u20136557. https:\/\/doi.org\/10.1016\/j.vaccine.2009.08.048","journal-title":"Vaccine"},{"issue":"6","key":"4096_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10067-013-2170-1","volume":"32","author":"CJ Zou","year":"2013","unstructured":"Zou CJ, Zhu LJ, Li YH, Mo YQ, Zheng DH, Ma JD, Ou-Yang X, Pessler F, Dai L (2013) The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. Clin Rheumatol 32(6):787\u2013795. https:\/\/doi.org\/10.1007\/s10067-013-2170-1","journal-title":"Clin Rheumatol"},{"issue":"2","key":"4096_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.21051","volume":"43","author":"W Yeo","year":"2006","unstructured":"Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43(2):209\u2013220. https:\/\/doi.org\/10.1002\/hep.21051","journal-title":"Hepatology"},{"issue":"7","key":"4096_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","volume":"148","author":"R Loomba","year":"2008","unstructured":"Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148(7):519\u2013528","journal-title":"Ann Intern Med"},{"issue":"1","key":"4096_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.03099.x","volume":"115","author":"G Rossi","year":"2001","unstructured":"Rossi G, Pelizzari A, Motta M, Puoti M (2001) Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115(1):58\u201362","journal-title":"Br J Haematol"},{"issue":"3","key":"4096_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/hep.22106","volume":"47","author":"C Hsu","year":"2008","unstructured":"Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ (2008) A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin\u2019s lymphoma: a randomized trial. Hepatology 47(3):844\u2013853. https:\/\/doi.org\/10.1002\/hep.22106","journal-title":"Hepatology"},{"issue":"3","key":"4096_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50(3):661\u2013662. https:\/\/doi.org\/10.1002\/hep.23190","journal-title":"Hepatology"},{"issue":"1","key":"4096_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1\u201326. https:\/\/doi.org\/10.1002\/art.39480","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4096_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association I (2015) American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148(1):215\u2013219; quiz e216\u2013217. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.039","journal-title":"Gastroenterology"},{"issue":"36","key":"4096_CR13","doi-asserted-by":"publisher","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","volume":"21","author":"S Mori","year":"2015","unstructured":"Mori S, Fujiyama S (2015) Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol 21(36):10274\u201310289. https:\/\/doi.org\/10.3748\/wjg.v21.i36.10274","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4096_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3350\/cmh.2016.0024","volume":"22","author":"V Pattullo","year":"2016","unstructured":"Pattullo V (2016) Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol 22(2):219\u2013237. https:\/\/doi.org\/10.3350\/cmh.2016.0024","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"4096_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/14712598.2016.1177017","volume":"16","author":"M Vigano","year":"2016","unstructured":"Vigano M, Serra G, Casella G, Grossi G, Lampertico P (2016) Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opin Biol Ther 16(7):917\u2013926. https:\/\/doi.org\/10.1080\/14712598.2016.1177017","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"4096_CR16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152(6):1297\u20131309. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.009","journal-title":"Gastroenterology"},{"key":"4096_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/1471-2474-15-449","volume":"15","author":"YQ Mo","year":"2014","unstructured":"Mo YQ, Liang AQ, Ma JD, Chen LF, Zheng DH, Schumacher HR, Dai L (2014) Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. BMC Musculoskelet Disord 15:449. https:\/\/doi.org\/10.1186\/1471-2474-15-449","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"4096_CR18","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1097\/MCG.0b013e31824e159c","volume":"46","author":"M Malespin","year":"2012","unstructured":"Malespin M, Wong S, Siqueira F, Luc B, Ravaee B, Vainder C, Cotler SJ (2012) Barriers to treatment of hepatitis B in an urban Chinatown community. J Clin Gastroenterol 46(8):e66\u2013e70. https:\/\/doi.org\/10.1097\/MCG.0b013e31824e159c","journal-title":"J Clin Gastroenterol"},{"key":"4096_CR19","unstructured":"National Health Institute. Quality assessment tool for case series studies. https:\/\/www.nhlbi.nih.gov\/health-pro\/guidelines\/in-develop\/cardiovascular-risk-reduction\/tools\/case_series . Accessed 20th May 2017"},{"issue":"7","key":"4096_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/jvh.12672","volume":"24","author":"Z Liu","year":"2017","unstructured":"Liu Z, Jiang L, Liang G, Song E, Jiang W, Zheng Y, Gong C (2017) Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: a review and meta-analysis of prophylaxis management. J Viral Hepat 24(7):561\u2013572. https:\/\/doi.org\/10.1111\/jvh.12672","journal-title":"J Viral Hepat"},{"issue":"6","key":"4096_CR21","doi-asserted-by":"publisher","first-page":"e0179680","DOI":"10.1371\/journal.pone.0179680","volume":"12","author":"YT Wu","year":"2017","unstructured":"Wu YT, Li X, Liu ZL, Xu Z, Dai W, Zhang K, Wu JS, Arshad B, Wu KN, Kong LQ (2017) Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: a systematic review and meta-analysis. PLoS One 12(6):e0179680. https:\/\/doi.org\/10.1371\/journal.pone.0179680","journal-title":"PLoS One"},{"issue":"5","key":"4096_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/14787210.2017.1309291","volume":"15","author":"MY Zhang","year":"2017","unstructured":"Zhang MY, Zhu GQ, Zheng JN, Cheng Z, Van Poucke S, Shi KQ, Huang HH, Chen FY, Zheng MH (2017) Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. Expert Rev Anti-Infect Ther 15(5):503\u2013513. https:\/\/doi.org\/10.1080\/14787210.2017.1309291","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"1","key":"4096_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/M15-1121","volume":"164","author":"S Paul","year":"2016","unstructured":"Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB (2016) Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med 164(1):30\u201340. https:\/\/doi.org\/10.7326\/M15-1121","journal-title":"Ann Intern Med"},{"issue":"6","key":"4096_CR24","doi-asserted-by":"publisher","first-page":"e0128673","DOI":"10.1371\/journal.pone.0128673","volume":"10","author":"W Tang","year":"2015","unstructured":"Tang W, Chen L, Zheng R, Pan L, Gao J, Ye X, Zhang X, Zheng W (2015) Prophylactic effect of lamivudine for chemotherapy-induced hepatitis B reactivation in breast cancer: a meta-analysis. PLoS One 10(6):e0128673. https:\/\/doi.org\/10.1371\/journal.pone.0128673","journal-title":"PLoS One"},{"issue":"2","key":"4096_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jfma.2012.10.007","volume":"114","author":"JY Liu","year":"2015","unstructured":"Liu JY, Sheng YJ, Ding XC, Tang H, Tong SW, Zhang DZ, Zhou Z, Hu P, Liao Y, Ren H, Hu HD (2015) The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. J Formosan Med Assoc Taiwan yi zhi 114(2):164\u2013173. https:\/\/doi.org\/10.1016\/j.jfma.2012.10.007","journal-title":"J Formosan Med Assoc Taiwan yi zhi"},{"issue":"1","key":"4096_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clinre.2014.07.010","volume":"39","author":"H Li","year":"2015","unstructured":"Li H, Zhang HM, Chen LF, Chen YQ, Chen L, Ren H, Hu HD (2015) Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 39(1):80\u201392. https:\/\/doi.org\/10.1016\/j.clinre.2014.07.010","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"4096_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/hep.29082","volume":"66","author":"S Paul","year":"2017","unstructured":"Paul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB (2017) Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology 66(2):379\u2013388. https:\/\/doi.org\/10.1002\/hep.29082","journal-title":"Hepatology"},{"issue":"5","key":"4096_CR28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s11096-016-0358-6","volume":"38","author":"S Yu","year":"2016","unstructured":"Yu S, Luo H, Pan M, Luis AP, Xiong Z, Shuai P, Zhang Z (2016) Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 38(5):1035\u20131043. https:\/\/doi.org\/10.1007\/s11096-016-0358-6","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"4096_CR29","first-page":"501","volume":"15","author":"C Yang","year":"2016","unstructured":"Yang C, Qin B, Yuan Z, Chen L, Zhou HY (2016) Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol 15(4):501\u2013511","journal-title":"Ann Hepatol"},{"issue":"4","key":"4096_CR30","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3748\/wjg.v22.i4.1727","volume":"22","author":"A Calica Utku","year":"2016","unstructured":"Calica Utku A, Karabay O (2016) Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations. World J Gastroenterol 22(4):1727\u20131728. https:\/\/doi.org\/10.3748\/wjg.v22.i4.1727","journal-title":"World J Gastroenterol"},{"issue":"6","key":"4096_CR31","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","volume":"37","author":"AL Cheng","year":"2003","unstructured":"Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J, Lymphoma Committee of Taiwan Cooperative Oncology G (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37(6):1320\u20131328. https:\/\/doi.org\/10.1053\/jhep.2003.50220","journal-title":"Hepatology"},{"key":"4096_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/926836","volume":"2014","author":"F Cantini","year":"2014","unstructured":"Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB (2014) HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-\u03b1) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int J Rheumatol 2014:1\u20139","journal-title":"Int J Rheumatol"},{"issue":"6","key":"4096_CR33","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0016-5085(81)80002-9","volume":"81","author":"GH Scullard","year":"1981","unstructured":"Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB (1981) Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81(6):987\u2013991","journal-title":"Gastroenterology"},{"issue":"1","key":"4096_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7326\/0003-4819-104-1-12","volume":"104","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, Jones EA, Seeff LB (1986) A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann Intern Med 104(1):12\u201317","journal-title":"Ann Intern Med"},{"issue":"2","key":"4096_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1440-1746.1996.tb00051.x","volume":"11","author":"IS Sheen","year":"1996","unstructured":"Sheen IS, Liaw YF, Lin SM, Chu CM (1996) Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors. J Gastroenterol Hepatol 11(2):143\u2013147","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4096-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4096-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4096-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T12:39:50Z","timestamp":1604147990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4096-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4096"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4096-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]},"assertion":[{"value":"22 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}